Steven R Schwid

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relap
    Steven R Schwid
    Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
    Clin Ther 29:2031-48. 2007
  2. ncbi A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
  3. ncbi A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010
  4. ncbi Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Arch Neurol 62:785-92. 2005
  5. ncbi Broadening the spectrum of controls for skin biopsy in painful neuropathies
    David N Herrmann
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Muscle Nerve 42:436-8. 2010
  6. ncbi Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
  7. ncbi Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
  8. ncbi Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 65:1964-6. 2005
  9. ncbi Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Andrew D Goodman
    University of Rochester, Rochester, NY, USA
    Lancet 373:732-8. 2009
  10. ncbi Cognitive fatigue during a test requiring sustained attention: a pilot study
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 9:503-8. 2003

Detail Information

Publications21

  1. ncbi Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relap
    Steven R Schwid
    Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
    Clin Ther 29:2031-48. 2007
    ..Interferon (IFN)-beta therapy represents an important advance in the management of relapsing multiple sclerosis (MS), but information about the relative benefits and risks of available preparations is limited...
  2. ncbi A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
    ..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
  3. ncbi A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010
    ..The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study...
  4. ncbi Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Arch Neurol 62:785-92. 2005
    ....
  5. ncbi Broadening the spectrum of controls for skin biopsy in painful neuropathies
    David N Herrmann
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Muscle Nerve 42:436-8. 2010
    ..Distal-leg ENFD/morphology in MS DLLBP patients did not differ significantly from that of healthy controls. This study extends the range of ENFD controls and further supports use of ENFD assessment in SFSN...
  6. ncbi Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
    ....
  7. ncbi Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  8. ncbi Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 65:1964-6. 2005
    ..The two groups were similar in the proportion of patients achieving an HI titer of 40 or greater, the prespecified primary end point and on all secondary indicators of immune response...
  9. ncbi Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Andrew D Goodman
    University of Rochester, Rochester, NY, USA
    Lancet 373:732-8. 2009
    ..This phase III study assessed efficacy and safety of oral, sustained-release fampridine in people with ambulatory deficits due to multiple sclerosis...
  10. ncbi Cognitive fatigue during a test requiring sustained attention: a pilot study
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 9:503-8. 2003
    ..Motor fatigue can be objectively measured as the decline in strength occurring during sustained contractions. Analogous declines in cognitive performance occur during tasks requiring sustained attention...
  11. ncbi Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 605, Rochester, NY 14586, USA
    Nat Clin Pract Neurol 5:82-92. 2009
    ..We propose that the potential role of PUFAs as disease-modifying, anti-inflammatory treatments for MS should be revisited in proof-of-concept trials that use accepted MRI outcome measures...
  12. ncbi Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  13. ncbi Pain associated with multiple sclerosis: systematic review and proposed classification
    Alec B O'Connor
    Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Pain 137:96-111. 2008
    ..Suggestions for future studies that would increase understanding of the natural history, mechanisms, and treatment of pain in patients with MS are presented...
  14. ncbi Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
    ....
  15. ncbi A randomized controlled study of the acute and chronic effects of cooling therapy for MS
    Steven R Schwid
    University of Rochester, Rochester, NY, USA
    Neurology 60:1955-60. 2003
    ..CONCLUSIONS: Cooling therapy was associated with objectively measurable but modest improvements in motor and visual function as well as persistent subjective benefits...
  16. ncbi Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  17. ncbi Treating fatigue in patients with MS: one step forward, one step back
    Steven R Schwid
    Neurology 64:1111-2. 2005
  18. ncbi Fatigue in multiple sclerosis: current understanding and future directions
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, NY, USA
    J Rehabil Res Dev 39:211-24. 2002
    ..Dividing fatigue into these components can provide objective assessments that are less likely to be confounded by other symptoms of MS, such as weakness, spasticity, cognitive impairment, and depressed mood...
  19. ncbi Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  20. ncbi Futility studies: spending a little to save a lot
    Steven R Schwid
    Neurology 66:626-7. 2006
  21. ncbi Multiple sclerosis, depression, and the risk of suicide
    Eric D Caine
    Neurology 59:662-3. 2002